Having a better understanding of what things are associated with LCHADD retinopathy can provide insight towards developing treatment. During this presentation, Dr. Gillingham will provide an update on the current results of a natural history study of 40 patients with LCHADD. She will also discuss what factors are associated with retinal structure and function, and how blood biomarkers or genetics might be related. Lastly, Dr. Gillingham will update our FAOD community about her lab’s efforts to treat retinopathy in an LCHADD mouse.
Mitochondrial Augmentation Technology (MAT) involves internalizing healthy, functional mitochondria into patient-derived cells to address mitochondrial dysfunction. Minovia has developed two generations of MAT products,...
Greg Macpherson, CEO of MitoQ, discusses “Mitochondria and MitoQ: A Research Update.” MitoQ’s mission is to raise awareness of mitochondria and the link between...
Friday, July 24Auditorium – 2:00pm – Infection, Immunity and FAOD About the Speaker Dr. Peter McGuire received his MBBCh (with Honours) from the Royal...
